Kings Arms Yard VCT PLC Interim Management Statement
Introduction
I am pleased to present Kings Arms Yard VCT PLC's interim management statement for the period from 1 July 2014 to 14 November 2014 as required by the UK Listing Authority's Disclosure and Transparency Rule 4.3.
Performance and dividends
The Company's unaudited net asset value (NAV), as at 30 September 2014 was £40.39 million or 19.92 pence per share (excluding treasury shares), a decrease of 0.06 pence per share or 0.30 per cent. since 30 June 2014.
After accounting for the dividend of 0.50 pence per share, which was paid on 31 October 2014 to shareholders on the register as at 3 October 2014, the NAV is 19.42 pence per share.
Share issues and buybacks
During the period from 1 July 2014 to 30 September 2014, the Company issued the following shares under the Albion VCTs Top Up Offers 2013/2014 and the Albion VCTs Prospectus Top Up Offers 2013/2014:
Date | Number of shares issued | Issue price per share (including costs of issue)* | Net proceeds £'000 |
4 July 2014 | 30,996 | 20.70 pence | 6 |
4 July 2014 | 9,615 | 20.80 pence | 2 |
4 July 2014 | 136,146 | 20.90 pence | 28 |
4 July 2014 (Prospectus) | 1,809,406 | 20.90 pence | 367 |
30 September 2014 (Prospectus) | 2,838,465 | 20.60 pence | 567 |
Total | 4,824,628 | 970 |
*The difference in the issue price per share reflects the "early bird" incentives as explained in the Albion VCT Top Up Offers 2013/2014 investor guide.
The Albion VCT Prospectus Top Up Offers 2013/2014 closed on 30 September 2014.
In total, 17,279,194 shares were issued under the Albion VCTs Top Up Offers 2013/2014 and the Albion VCTs Prospectus Top Up Offers 2013/2014, raising net proceeds of £3.45 million.
Total shares issued under the Albion VCTs Top Up Offers 2013/2014 and the Albion VCTs Prospectus Top Up Offers 2013/2014 | Number of shares issued | Net proceeds £'000 |
31 January 2014 | 4,668,113 | 878 |
5 April 2014 | 7,786,453 | 1,601 |
4 July 2014 | 1,986,163 | 403 |
30 September 2014 | 2,838,465 | 567 |
Total | 17,279,194 | 3,449 |
The proceeds of the Offers are being used to provide further resources to the Company at a time when a number of attractive new investment opportunities are being seen.
In addition, the following shares were issued under the dividend reinvestment scheme:
Date | Number of shares issued | Issue price per share | Net proceeds £'000 |
31 October 2014 | 262,169 | 19.48 | 49 |
During the period from 1 July 2014 to 14 November 2014, the Company purchased 2,245,000 shares for £418,000 at an average price of 18.60 pence per share. All of the shares are to be held in treasury
It remains the Board's policy to buy back shares in the market, subject to the overall constraint that such purchases are in the Company's interest, including the maintenance of sufficient resources for investment in existing and new portfolio companies and the continued payment of dividends to shareholders. It is the Board's intention for such buy-backs to be at around a 5 per cent. discount to net asset value, so far as market conditions and liquidity permit.
Portfolio
The following investments have been made during the period from 1 July 2014 to 14 November 2014:
New investments | £000's | Activity |
Omprompt Limited | 900 | Business to business integration software. |
Infinite Ventures (Goathill) Limited | 112 | Wind turbine project in Scotland |
Total new investments | 1,012 | |
Further investments | £000's | Activity |
Elateral Group Holdings Limited | 450 | Provider of digital marketing software |
Chonais Holdings Limited | 423 | Hydropower project in Scotland |
MyMeds&Me Limited | 219 | Software for managing pharmaceutical adverse events |
Green Highland Renewables (Ledgowan) Limited | 180 | Hydropower project in Scotland |
Proveca Limited | 179 | Repositioning of pediatric medicines |
Relayware Limited | 93 | Business collaboration and communication solutions. |
Mirada Medical Limited | 68 | Developer of medical imaging software |
Taunton Hospital Limited | 66 | Owner and operator of a psychiatric hospital |
Haemostatix Limited | 62 | Developer of topical and systematic clotting agents |
Cisiv Limited | 37 | Software and services for non-interventional clinical trials |
Total further investments | 1,777 |
Disposals and loan stock repayments
The following disposals and loan stock repayments were made during the period from 1 July 2014 to 14 November 2014:
Name | £000's | |
Clear2Pay NV | 156 | Disposal of investment |
Hilson Moran Holdings Limited | 80 | Loan stock and redemption premium repayment |
Isango! Limited | 3 | Final proceeds on disposal |
Total proceeds | 239 |
Top ten holdings as at 30 September 2014:
Investment | Carrying value £000's | % of net asset value | Activity |
Elateral Group Holdings Limited | 5,236 | 13.0% | Provider of digital marketing software |
Oxford Immunotec Global PLC | 3,685 | 9.1% | A global, commercial-stage diagnostic company in the field of immunology |
Sift Limited | 2,642 | 6.5% | Web based provision of online business and community management solutions |
Cluster Seven Ltd | 2,437 | 6.0% | Design and development of spreadsheet management software for risk control and compliance |
Active Lives Cares Limited | 1,938 | 4.8% | Owner and operator of a residential care home for the elderly in Oxford. |
Chonais Holdings Limited | 1,619 | 4.0% | Hydropower project in Scotland |
The Street by Street Solar Programme Limited | 1,373 | 3.4% | Builds, owns and operates photovoltaic systems on domestic properties in the UK |
Alto Prodotto Wind Limited | 1,340 | 3.3% | Owns and operates community scale wind energy projects on brownfield sites in the UK |
Lab M Holdings Limited | 1,315 | 3.3% | Microbiological testing products |
Hilson Moran Holdings Limited | 1,125 | 2.8% | Multi-disciplinary engineering consultancy |
A full breakdown of the Company's portfolio can be found on the funds website under current portfolio at www.albion-ventures.co.uk/ourfunds/KAY.htm.
Material events and transactions
There have been no further significant events or transactions that the Board is aware of which would have a material impact on the financial position of the Company between 1 July 2014 and 14 November 2014.
Further information
The Company continues to offer a Dividend Reinvestment Scheme to existing shareholders. Details of this Scheme can be found at www.albion-ventures.co.uk/ourfunds/KAY.htm.
Further information regarding historic and current financial performance and other useful shareholder information can be found on the Fund's website under www.albion-ventures.co.uk/ourfunds/KAY.htm.
Robin Field, Chairman
14 November 2014
For further information please contact:
Patrick Reeve, Albion Ventures LLP - Tel: 020 7601 1850